These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33618662)

  • 1. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
    Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
    BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
    Mojica MF; Papp-Wallace KM; Taracila MA; Barnes MD; Rutter JD; Jacobs MR; LiPuma JJ; Walsh TJ; Vila AJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784669
    [No Abstract]   [Full Text] [Related]  

  • 4.
    Crémet L; Joffraud L; Eschapasse E; Bihouée T; Tissot A; Gibaud S; Persyn E
    Microb Drug Resist; 2022 Aug; 28(8):877-881. PubMed ID: 35763306
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Wang W; Huang S; Zou C; Ding Y; Wang H; Pu S; Liao Y; Du H; Wang D; Chen L; Niu S
    Front Cell Infect Microbiol; 2021; 11():755763. PubMed ID: 34778107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli.
    Tao L; Dahlquist A; Harris H; Jacobs E; Wenzler E; Simner PJ; Humphries R
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0069324. PubMed ID: 39158279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection.
    Rawson TM; Brzeska-Trafny I; Maxfield R; Almeida M; Gilchrist M; Gonzalo X; Moore LS; Donaldson H; Davies F
    J Glob Antimicrob Resist; 2022 Jun; 29():558-562. PubMed ID: 35131508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone.
    Moriceau C; Eveillard M; Lemarié C; Chenouard R; Pailhoriès H; Kempf M
    Med Mal Infect; 2020 May; 50(3):305-307. PubMed ID: 32014291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple disk pre-diffusion test to predict in vitro aztreonam/avibactam activity against NDM-producing Klebsiella pneumoniae complex.
    Lima KO; de Lima AV; Rocha DADC; Sampaio SCF; Cappellano P; Sampaio JLM
    J Glob Antimicrob Resist; 2022 Mar; 28():49-52. PubMed ID: 34936924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Looking for
    Ranieri EM; Denicolò S; Stolfa S; Dalfino L; Bavaro DF; Saracino A; Ronga L; Del Prete R; Mosca A
    J Chemother; 2023 Nov; 35(7):610-613. PubMed ID: 37615040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam.
    Yang X; Wang D; Zhou Q; Nie F; Du H; Pang X; Fan Y; Bai T; Xu Y
    BMC Microbiol; 2019 Nov; 19(1):240. PubMed ID: 31675928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilli.
    Deckers C; Bélik F; Denis O; Bogaerts P; Montesinos I; Berhin C; Bouchahrouf W; Hoebeke M; Evrard S; Gilliard N; Okur M; Huang TD
    Ann Clin Microbiol Antimicrob; 2024 May; 23(1):47. PubMed ID: 38796461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017).
    Rossolini GM; Stone GG
    Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant
    Kim T; Lee SC; Bae M; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Chong YP
    Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33334045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
    López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study.
    Wei J; Zou C; Wang D; Huang A; Niu S
    J Glob Antimicrob Resist; 2020 Sep; 22():448-451. PubMed ID: 32387260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from
    Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S
    Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant
    Sun S; Chen K; Kong X; Tian W; Niu S
    Infect Drug Resist; 2022; 15():2243-2251. PubMed ID: 35510161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.